[Medical treatment of soft tissue sarcomas based on the histological subtype].
The medical treatment of adult soft tissue sarcomas is more and more dictated by the histological subtype, this applies to both cytotoxics and target therapies. Doxorubicin and ifosfamid are the two drugs used either in monotherapy or combination with the best established response rates in adult soft tissue sarcomas for several years. In addition to these compounds there is evidence of efficacy of new drugs such as taxanes in angiosarcoma, gemcitabine+taxanes combination in leiomyosarcomas, trabectedin in leiomyosarcomas and liposarcomas with an extremely high activity in myxoid liposarcoma. With regard to target therapy pazopanib seems especially active in leiomyosarcomas and synoviosarcomas, but totally inactive in liposarcomas, sunitinib and cediranib in alveolar soft part sarcomas, sunitinib and bevacizumab+temozolamide combination in solitary fibrous tumors, and sorafenib in angiosarcomas. mTOR inhibitors are active in PEComas (perivascular epitheloid cell tumors) and crizotinib in ALK rearranged inflammatory myofibroblastic tumors. The efficacy of imatinib and sunitinib in GIST tumors are established, and that of imatinib in dermatofibrosarcoma as well.
Onkológiai Osztály, MH-Egészségügyi Központ, Budapest, Hungary. zspapai@gmail.com.
Zsuzsanna
Z
Pápai
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy; D006393:Hemangiopericytoma / Q000188:drug therapy; D006394:Hemangiosarcoma / Q000188:drug therapy; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy; D008080:Liposarcoma / Q000188:drug therapy; D058990:Molecular Targeted Therapy / Q000379:methods; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology*; D012514:Sarcoma, Kaposi / Q000188:drug therapy; D013584:Sarcoma, Synovial / Q000188:drug therapy; D054364:Solitary Fibrous Tumors / Q000188:drug therapy